The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended Jinarc (tolvaptan), from Otsuka Pharmaceutical,...
Teva Pharmaceutical announced that the New Drug Application (NDA) for SD 809 (deutetrabenazine) has been accepted by the FDA for...
Astellas UK has been suspended from the Association of the British Pharmaceutical Industry. It has been accused of sending doctors...
Alexza Pharmaceuticals, Inc. announced that they have entered into an exclusive U.S. license and supply agreement with Teva Pharmaceutical Industries...
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase III RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis
ImmunoGen, Inc. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd., announced that the companies have entered into an exclusive collaboration to develop and commercialize mirvetuximab soravtansine in mainland China, Hong Kong, Macau, and Taiwan (Greater China).
Ultragenyx Pharmaceutical Inc. a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Dimension...
Zhejiang Huahai Pharmaceutical has agreed with Breckenridge Pharmaceutical to market, in the USA, a generic version of Viramune (nevirapine) currently...
Impax Laboratories, Inc. a specialty pharmaceutical company, announced that it has signed definitive agreements with Teva Pharmaceutical Industries Ltd. and...
Shionogi said that its group company Ping An-Shionogi (Hong Kong) has concluded a sublicense agreement to grant South Korea’s Jeil Pharmaceutical the exclusive rights to develop and market the new siderophore cephalosporin antibacterial drug cefiderocol in the country